Upstream Bio, Inc. (UPB)
NASDAQ:UPB
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$5.14 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)388.50K
Market Cap
$456.63M
Enterprise Value$385.88M
Total Cash (Recent Filing)$372.43M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,038,590
10 Day Avg. Volume473,530
30 Day Avg. Volume388,499
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)1.80
Price to Sales (P/S)356.14
P/FCF Ratio-14.14
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue137.86
Enterprise Value/Gross Profit139.41
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$52.67Price Target Upside73.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$1.54M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase II results indicate verekitug delivered efficacy comparable to an approved TSLP inhibitor while enabling less frequent dosing, which could translate into a meaningful commercial advantage if replicated in registrational studies.
Physician Adoption PotentialSurveys of high-volume allergy and pulmonology physicians show strong willingness to prescribe verekitug and a preference for the lower-dose regimen, indicating potential for favorable uptake in the biologic-eligible patient pool.
Regulatory And Development PathInitiation of planning for registrational Phase III trials and planned regulatory interactions suggest a clearer development path that could unlock value once dose selection and trial design are finalized.
Bears Say
Competitive Pressure From Established BiologicsRapid growth of a competing biologic and the market advantage of a six-month dosing schedule heighten competitive pressure and could constrain market share for newer entrants without a clear differentiation.
Dosing Strategy RiskUndefined Phase III dosing strategy introduces regulatory and execution uncertainty, as lack of an optimal dose could delay trials or necessitate additional studies before approval.
Financing And Near-term Catalyst RiskNeed for additional capital to support multiple Phase III programs combined with a shortage of near-term clinical catalysts increases financing risk and could weigh on the stock if fundraising conditions are unfavorable.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $456.63M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is May 12, 2026 which is in 47 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,038,590 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.67 (73.82% Upside)
$52.67 (73.82% Upside)
Hedge Fund Trend
Increased
By 141.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $46.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 27.0%
Last 30 Days ▲ 27.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.21%
12-Months-Change
Fundamentals
Return on Equity
-28.71%
Trailing 12-Months
Asset Growth
68.11%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.
UPB Stock 12 Month Forecast
Average Price Target
$52.67
▲(73.82% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.75% Insiders
19.29% Mutual Funds
44.29% Other Institutional Investors
18.23% Public Companies and
Individual Investors